Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tonix Pharmaceuticals Holding Corp.

Get SEC filing alerts via email and in your feed for Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a biopharmaceutical company focused on developing therapeutics and vaccines for central nervous system disorders, infectious diseases, immunology, and rare diseases. Its portfolio includes drug candidates for fibromyalgia, PTSD, addiction, autoimmune conditions, and infectious diseases like smallpox and mpox. The company also markets FDA-approved migraine treatments and leverages proprietary formulations, innovative pipelines, and strategic collaborations to address high unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tonix Pharmaceuticals Holding Corp.

1
1
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Reports $6.9M Revenue and $40.2M Net Loss for Q1 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Reports 2025 Financial Results and Product Developments

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Reports Increased Q3 Losses Amid Rising Revenue and Upcoming Product Launch

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Reports $28.3 Million Net Loss in Q2 2025, Focuses on Product Development

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Reports Q1 2025 Financial Results with $2.4M Revenue and $16.8M Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Reports $130M Net Loss and $10.1M Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Reports Mixed Financial Results for Q3 2024, Reduces Losses and Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments